Alpelisib (BYL719) is a potent, selective PI3Kα inhibitor. It affects PI3K/AKT/mTOR signaling by inhibiting PI3K activity and inducing p110α degradation, effectively suppressing cancer cell proliferation and inducing apoptosis.
Alpelisib (BYL719) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for Alpelisib (BYL719) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.